Nature, Published online: 15 January 2025; doi:10.1038/d41586-024-04156-wA phase I clinical trial of GD2-CAR T cells (immune cells engineered to target the molecule GD2) in children and young adults with diffuse midline gliomas incurable cancers of the central nervous system shows promising results. Several trial participants exhibited substantial improvements, and one childs tumour has been undetectable for more than three years.